In last trading session, 89bio Inc (NASDAQ:ETNB) saw 0.31 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $8.06 trading at -$1.08 or -11.82% at ring of the bell on the day assigns it a market valuation of $947.71M. That closing price of ETNB’s stock is at a discount of -106.33% from its 52-week high price of $16.63 and is indicating a premium of 13.15% from its 52-week low price of $7.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.94 million shares which gives us an average trading volume of 695.95K if we extend that period to 3-months.
For 89bio Inc (ETNB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.73 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
89bio Inc (NASDAQ:ETNB) trade information
Upright in the red during last session for losing -11.82%, in the last five days ETNB remained trading in the red while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $8.06 price level, adding 15.16% to its value on the day. 89bio Inc’s shares saw a change of -27.84% in year-to-date performance and have moved -3.82% in past 5-day. 89bio Inc (NASDAQ:ETNB) showed a performance of 0.88% in past 30-days. Number of shares sold short was 5.52 million shares which calculate 6.55 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 25 to the stock, which implies a rise of 67.76% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 29. It follows that stock’s current price would drop -48.88% in reaching the projected high whereas dropping to the targeted low would mean a loss of -48.88% for stock’s current value.
89bio Inc (ETNB) estimates and forecasts
Statistics highlight that 89bio Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 2.03% of value to its shares in past 6 months, showing an annual growth rate of -61.00% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.24% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -58.84% while estimates for its earnings growth in next 5 years are of 11.00%.
89bio Inc (NASDAQ:ETNB)’s Major holders
Insiders are in possession of 0.58% of company’s total shares while institution are holding 93.67 percent of that, with stock having share float percentage of 94.22%. Investors also watch the number of corporate investors in a company very closely, which is 93.67% institutions for 89bio Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at ETNB for having 14.18 million shares of worth $113.54 million. And as of 2024-06-30, it was holding 14.1994 of the company’s outstanding shares.
The second largest institutional holder is JANUS HENDERSON GROUP PLC, which was holding about 13.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 13.2986 of outstanding shares, having a total worth of $106.32 million.
On the other hand, Janus Henderson Global Life Sciences Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.96 shares of worth $26.58 million or 2.79% of the total outstanding shares. The later fund manager was in possession of 2.57 shares on Jun 30, 2024 , making its stake of worth around $23.09 million in the company or a holder of 2.42% of company’s stock.
